Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2010-03-08 Director's Dealing
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
L. RAHN STOCK OPTION GRANT 03/2010
Director's Dealing
2010-03-08 English
E. FRYKMAN STOCK OPTION GRANT 03/04/2010
Director's Dealing
2010-03-08 English
C. ANZALONE STOCK OPTION GRANT 03/2010
Director's Dealing
2010-03-08 English
FORM 10-Q
Interim / Quarterly Report Q1 2010
2010-02-11 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 11, 2010, reporting the results of operations and financial condition for the quarter ended December 31, 2009. It includes a press release as an exhibit announcing quarterly financial results. The text explicitly states it is a Current Report on Form 8-K, which is used for unscheduled material events or corporate changes. The document is short (2725 characters) and primarily announces financial results via a press release, not the full financial statements or detailed analysis. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2010-02-11 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 1, 2010, reporting the appointment of a new Chief Financial Officer and related compensatory arrangements. The content focuses on management changes, specifically the departure and appointment of officers. There are no financial statements or detailed financial performance data present. The document fits the category of announcements related to changes in the company's board or senior management rather than a full annual or quarterly report, audit report, or earnings release. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4750 characters, which is sufficient to contain substantive information about management changes rather than a brief announcement or certification.
2010-02-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.